Annual report
2269.TEDINET S100R9C9
Period2022-04-01 → 2023-03-31
Filed2023-06-29
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.06T | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥1.01T | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥1.19T | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.25T | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.25T | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥75.4bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥92.9bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥74.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥94.0bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥110.2bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥103.3bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥99.7bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥95.4bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥128.5bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥69.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥87.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥65.7bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥67.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥61.9bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥71.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥92.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥1.14T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.12T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.07T | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥998.9bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.00T | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥384.9bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥404.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥751.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥713.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥659.4bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥597.6bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥560.6bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥63.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥67.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥60.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥64.9bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥39.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥37.1bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥24.5bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥85.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥127.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥123.7bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥114.1bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥112.1bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥36.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥27.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥93.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥70.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥100.2bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥54.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥77.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥28.3bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥30.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥14.0bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥247.39 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥303.62 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥226.26 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥232.04 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥213.3 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,553.69 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,390.76 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,141.4 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,939.59 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,817.89 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 62.7% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.3% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.2% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.3% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.5% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 10.0% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.5% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 11.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.4% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.2% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 17,290 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 17,336 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 17,832 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 17,571 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 17,608 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥28.1bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥34.5bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥25.5bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥23.3bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥21.6bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥23.2bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥30.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥23.9bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥31.1bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥22.9bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥21.1bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥19.9bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥28.9bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥31.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥28.3bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥31.7bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥22.4bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥21.1bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥19.8bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥369.2bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥391.4bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥386.1bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥378.8bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥385.7bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥130.8bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥145.4bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥238.4bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥246.0bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥266.1bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥262.2bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥265.9bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥7.9bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥11.5bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥100.97 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥110.12 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥77.03 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥72.84 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.35 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥180 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥170 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥160 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥150 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥140 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥855.11 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥873.6 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥917.04 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥903.8 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥916.55 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 64.6% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.9% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.9% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.2% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.9% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 11.7% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.4% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.5% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.0% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 148,369,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 148,369,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 152,683,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 152,683,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 152,683,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 99 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 85 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 66 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 54 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 34 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥214m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥233m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥732m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥732m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | −¥12.9bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥2.2bn |
| Foodreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥41.0bn |
| Foodreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥43.6bn |
| Foodreportable segment | employees | at 2023-03-31 | 10501 pure |
| Foodreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥865.6bn |
| Foodreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥864.9bn |
| Foodreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥714m |
| Foodreportable segment | segment assets | at 2023-03-31 | ¥823.0bn |
| Foodreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥55.9bn |
| Pharmaceuticalsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥11.3bn |
| Pharmaceuticalsreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥9.7bn |
| Pharmaceuticalsreportable segment | employees | at 2023-03-31 | 6685 pure |
| Pharmaceuticalsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥197.3bn |
| Pharmaceuticalsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥197.3bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥17m |
| Pharmaceuticalsreportable segment | segment assets | at 2023-03-31 | ¥326.1bn |
| Pharmaceuticalsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥21.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥52.3bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥53.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥1.06T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥1.06T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥732m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥1.15T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥77.6bn |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥191m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥223m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥969m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥969m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | −¥7.2bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥1.7bn |
| Foodreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥79.9bn |
| Foodreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥40.6bn |
| Foodreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥826.1bn |
| Foodreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥825.5bn |
| Foodreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥629m |
| Foodreportable segment | segment assets | at 2022-03-31 | ¥796.7bn |
| Foodreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥76.0bn |
| Pharmaceuticalsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥15.4bn |
| Pharmaceuticalsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥9.3bn |
| Pharmaceuticalsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥188.0bn |
| Pharmaceuticalsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥187.6bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥340m |
| Pharmaceuticalsreportable segment | segment assets | at 2022-03-31 | ¥327.9bn |
| Pharmaceuticalsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥18.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥95.3bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥49.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥1.01T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥1.01T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥969m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥1.12T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥94.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,881
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 17 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 1.127 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.984 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.935 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.893 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.878 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 0.950 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 0.859 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.221 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.246 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.318 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E21902-000FoodReportableSegmentsMember | 10501 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E21902-000FoodReportableSegmentsMember | 4675 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E21902-000PharmaceuticalsReportableSegmentsMember | 6685 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E21902-000PharmaceuticalsReportableSegmentsMember | 2535 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 104 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 32 | |
| Number of employees | CurrentYearInstant | 17290 | |
| Average number of temporary workers | CurrentYearInstant | 7242 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 99 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 17 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 44.9 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 20.8 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 10136000 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 99 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 17 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 99 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 17 | |
| Research and development expenses research and development activities | CurrentYearDuration | 30989000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E21902-000FoodReportableSegmentsMember | 13604000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E21902-000PharmaceuticalsReportableSegmentsMember | 16386000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 60591000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E21902-000FoodReportableSegmentsMember | 49568000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E21902-000PharmaceuticalsReportableSegmentsMember | 10861000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 148369500 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 293459000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 148369500 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 293459000 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 141 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 37 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 813 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 680 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 75 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 96733 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 98479 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 531166 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 33564 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |